Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia

被引：34
作者：
Chou, JM
Li, CY
Tefferi, A
机构：
[1] Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA
[2] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Pathol, Div Hematopathol, Taipei, Taiwan
[3] Mayo Clin & Mayo Fdn, Div Hematopathol, Rochester, MN 55905 USA
来源：
LEUKEMIA RESEARCH | 2003年 / 27卷 / 06期
关键词：
basic fibroblast growth factor; bone marrow; cytokine; immunohistochemistry; myelofibrosis; platelet-derived growth factor; transforming growth factor; vascular endothelial growth factor;
D O I：
10.1016/S0145-2126(02)00268-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bone marrow specimens from I I patients with myelofibrosis with myeloid metaplasia (MMM) and seven normal controls were studied immumohistochemically to determine expression of transforming growth factor beta(TGF-beta), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and corresponding receptors. Staining distribution and intensity for TGF-beta, PDGF, VEGF, TGF-beta type II receptor, a receptor for PDGF, and receptors for VEGF and bFGF were similar in patients and controls. Bone marrow from 10 MMM patients showed increased TGF-beta type I receptor (TGF-betaRI) expression in small vessel endothelial cells. Eight patient specimens had bFGF overexpression in megakaryocytes. Increased microvessel density and decreased concentration of bFGF-staining stromal cells accompanied these changes. Microvascular TGF-betaRI upregulation and bFGF overexpression by megakaryocytes may cause bone marrow microenvironmental changes in MMM patients. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：499 / 504
页数：6
相关论文
共 48 条
[1]  
Amizuka N, 1998, MICROSC RES TECHNIQ, V41, P313
[2]   Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis [J].
Anderson, JE ;
Tefferi, A ;
Craig, F ;
Holmberg, L ;
Chauncey, T ;
Appelbaum, FR ;
Guardiola, P ;
Callander, N ;
Freytes, C ;
Gazitt, Y ;
Razvillas, B ;
Deeg, HJ .
BLOOD, 2001, 98 (03) :586-593
[3]   Vascular development: Cellular and molecular regulation [J].
Beck, L ;
DAmore, PA .
FASEB JOURNAL, 1997, 11 (05) :365-373
[4]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[5]  
Chen QS, 1999, INT J HEMATOL, V70, P155
[6]   Pioneer axon guidance by UNC-129, a C-elegans TGF-β [J].
Colavita, A ;
Krishna, S ;
Zheng, H ;
Padgett, RW ;
Culotti, JG .
SCIENCE, 1998, 281 (5377) :706-709
[7]   Of worms and men: An evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families [J].
Coulier, F ;
Pontarotti, P ;
Roubin, R ;
Hartung, H ;
Goldfarb, M ;
Birnbaum, D .
JOURNAL OF MOLECULAR EVOLUTION, 1997, 44 (01) :43-56
[8]   Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: Evidence for a role of extracellular calmodulin in fibroblast proliferation [J].
Dalley, A ;
Smith, JM ;
Reilly, JT ;
MacNeil, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :856-862
[9]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[10]  
DICKSON MC, 1995, DEVELOPMENT, V121, P1845
12345